Active targeting of brain tumors using nanocarriers

Area of Science:

• Neuroscience
• Pharmacology
• Oncology

Background:

• The blood-brain barrier (BBB) significantly restricts drug delivery to brain tumors.
• Understanding brain capillary endothelium mechanisms is crucial for developing enhanced drug delivery strategies.
• Active targeting using site-specific ligands offers a non-invasive approach to transport drugs to target organs.

Purpose of the Study:

• To review targeted colloidal systems for drug delivery to the brain.
• To discuss the pharmacological behavior and therapeutic effects of these nanocarriers.
• To highlight advancements in overcoming BBB limitations for brain tumor treatment.

Main Methods:

• Review of literature on drug-loaded nanocarriers designed for brain delivery.
• Analysis of strategies involving endogenous and chimeric ligands conjugated to nanocarriers.
• Indexing of targeted colloidal systems interacting with BBB receptors and tumoral cells.

Main Results:

• Drug-loaded nanocarriers show promise in recognizing and targeting brain capillary endothelial and tumoral cells.
• Conjugation of ligands to nanocarriers facilitates enhanced drug penetration into brain tissue.
• Targeted nanocarriers demonstrate potential for improved therapeutic outcomes in brain oncology.

Conclusions:

• Targeted nanocarriers represent a promising strategy for overcoming BBB challenges in brain drug delivery.
• Further research into the pharmacological behavior and therapeutic effects of these systems is warranted.
• Active targeting approaches hold significant potential for advancing brain tumor treatment.